J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
The Rybrevant combination therapy by Johnson & Johnson (J&J) continues to be effective after three years in a study of…
Oncology
-
-
Cairn Surgical meets enrolment goal for breast cancer locator device trial
Cairn Surgical has completed enrolment in Europe for a clinical trial evaluating its personalised device for breast cancer surgery. The…
-
Avenzo and Gilead partner for breast cancer combination regimen trial
Avenzo Therapeutics has announced a clinical trial partnership and supply agreement with Gilead Sciences to assess a combination treatment regimen…
-
Theolytics secures grant from Innovate UK for Phase I trial of ovarian cancer drug
UK-based biotechnology company Theolytics has received a £2m ($2.6m) grant to support a Phase I clinical trial of its lead…
-
Pipeline Moves: Investigator-led oncology cell therapy trial terminated
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
-
ImCheck scores $22.4m in French funding to develop cancer antibody
ImCheck Therapeutics has received €20.18m ($22.35m) in non-dilutive funding from the French government to advance its pipeline. The funds were…
-
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets
Repare Therapeutics plans to reduce its workforce by around 25% as the company prioritises operations on its four clinical programmes…
-
Mabwell receives approval for Phase III trial of urothelial carcinoma drug in China
US-based biopharmaceutical company Mabwell Therapeutics has received approval from China's National Medical Products Administration (NMPA) to begin a Phase III…
-
GI Innovation and MSD partner for trial of GI-102 and Keytruda regimen for cancer
South Korean biotech company GI Innovation has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD)…
-
BioNTech initiates global trials of mRNA-based lung cancer vaccine
BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small…
